Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1243

Shown on this page

Current sort

Live official records

Conditions: Food Allergy, Early Allergen Introduction
Interventions: Education and Reminders/Supportive Communication, Education; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 4 Months to 8 Months
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Little Rock, Arkansas • New Haven, Connecticut • Dallas, Texas

Conditions: Non-Small Cell Lung Cancer, c-MET
Interventions: Telisotuzumab Vedotin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 40
States / cities: Chandler, Arizona • Little Rock, Arkansas • Los Angeles, California + 35 more

Conditions: Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
Interventions: PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI, FOLFOX, Gemcitabine, Mirvetuximab Soravtansine, Trastuzumab Deruxtecan; Biological · Drug
Lead sponsor: Pheast Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 20
States / cities: Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more

Conditions: Peripheral Arterial Disease, Atherosclerosis of Extremities, Inflammation
Interventions: Colchicine 0.5 MG Oral Tablet, Colchicine-Placebo; Drug
Lead sponsor: Population Health Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 6,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 24
States / cities: New Haven, Connecticut • Gainesville, Florida • Tampa, Florida + 19 more

Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions: Standard of Care Chemotherapy, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Intraperitoneal Port Placement, Magnetic Resonance Imaging, Intraperitoneal Paclitaxel; Drug · Procedure
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 78
States / cities: Irvine, California • Los Angeles, California • Orange, California + 64 more

Conditions: AML, MDS
Interventions: TSC-101, Control; Drug · Other
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 26
States / cities: Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 21 more

Conditions: Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8, Stage IVA Sinonasal Cancer AJCC v8, Stage IVB Sinonasal Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Carboplatin, Cemiplimab, Chemoradiotherapy, Cisplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Positron Emission Tomography, Radiation Therapy, Surgical Procedure; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Irvine, California • Los Angeles, California • Orange, California + 13 more

Conditions: AML, MDS
Interventions: SOC + TSC-101, Control, SOC + TSC-100; Drug · Other
Lead sponsor: TScan Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 21
States / cities: Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more

Conditions: Depressive Disorder, Major
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 32
States / cities: Moorpark, California • Orange, California • New Haven, Connecticut + 29 more

Conditions: Gastroesophageal Adenocarcinoma
Interventions: Tislelizumab, Leucovorin, Oxaliplatin, Fluorouracil, Zanidatamab, Zolbetuximab; Drug
Lead sponsor: American Association for Cancer Research; Other
Eligibility: 18 Years and older
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Los Angeles, California • New Haven, Connecticut • Houston, Texas

Conditions: Myelofibrosis
Interventions: Nusivertib, Ruxolitinib, Momelotinib; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 32
States / cities: Birmingham, Alabama • Tucson, Arizona • Duarte, California + 25 more

Conditions: Mantle Cell Lymphoma
Interventions: Zanubrutinib, Rituximab, Patient Observation, Bone Marrow Biopsy, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Magnetic Resonance Imaging, Esophagogastroduodenoscopy, Colonoscopy, Biospecimen Collection, Questionnaire Administration; Drug · Biological · Other + 1 more
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 60 Years and older
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2038
U.S. locations: 238
States / cities: Little Rock, Arkansas • Beverly Hills, California • Duarte, California + 185 more

About this Yale institution page

What this page lists: ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Yale

Filter and sort this campus

Live official records

Food Introduction for Risk Reduction, Support Tolerance: Behavioral Intervention for Toddler Eating Success

A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

A Study of PHST001 in Advanced Solid Tumors

Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

A Study of Brenipatide in Adult Participants With Major Depressive Disorder

AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

About this Yale institution page